Desvenlafaxine Succinate side effects: what 26,837 FDA adverse event reports show
Drug class
Not stated in label
Who reports
26,837 reports · 43% serious · 841 with death outcome · 77% female
Used for
Desvenlafaxine extended-release tablets are indicated for the treatment of adults with major depressive disorder (MDD) . Desvenlafaxine Extended-Release Tablets are a serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for the treatment of adults with major depressive disorder (MDD) ( 1 ).
What it is
Desvenlafaxine extended-release tablets are an extended-release tablets for oral administration that contain desvenlafaxine succinate, a structurally novel SNRI for the treatment of MDD. Desve.
Boxed warning
SUICIDAL THOUGHTS AND BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies. These studies did not show an increase in the ris.
Causality screen of the 40 strongest signals
What the badges mean
- Labeled — boxed warning The term (or its clinical synonym) appears in the FDA boxed warning: causality is regulator-recognised and considered serious.
- Labeled adverse reaction The exact term appears in the label's warnings or adverse-reactions sections: a known, expected effect. The FAERS signal confirms the label rather than discovering anything.
- Labeled (related wording) The label describes this effect under different wording (e.g. 'neutropenia' for 'neutrophil count decreased'). Treated as known.
- Likely indication confounding The term appears in the label's indications: reports probably describe the disease being treated (or its progression), not a drug effect. Classic confounding by indication.
- Reporting / coding artifact An administrative, monitoring or exposure term (product issue, off-label use, 'test normal', overdose...). Not a biological reaction; a high PRR here reflects how reports are coded.
- Lab value / disease marker A laboratory result, investigation or disease-activity marker (antibody positive, CRP abnormal, swollen joint count) not described in the label. These usually mirror the monitored disease or testing protocol rather than a drug effect; not screened further.
- Not in label — unassessed Not found in the label text, not an artifact pattern. This is a genuine candidate for a formal causality assessment (Bradford Hill / WHO-UMC); it has NOT had one here.
Strongest disproportionality signals
Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only (and, for the 300 most-reported drugs, adjusted for age band), and flags pairs whose reports are unusually skewed by sex or come mostly from consumers. Each row also shows the PRR against the other drugs of the same FDA class, which removes most confounding by the condition being treated, and a calibrated p-value: on validation, known non-causes average an ROR of about 2, so significance is judged against that empirical null (✓ = p < 0.05 after calibration). 1,110 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Gastric ileus | 18 | 420.0 236.5–745.8ROR 420.3 · calibrated p 1e-11 ✓ | 211.3 EB05 141.4 · IC025 +4.2 3/3 methods agree | Not in label — unassessed | serious n=18 | not reported in cached trials |
| Medication residue | 533 | 200.3 182.2–220.1ROR 204.3 · calibrated p 3e-10 ✓ | 158.3 EB05 147.3 · IC025 +7.0 3/3 methods agree | Not in label — unassessed | serious n=41 | not reported in cached trials |
| Persistent genital arousal disorder | 20 | 73.3 46.4–116.0ROR 73.4 · calibrated p 3e-6 ✓ | 63.2 EB05 43.2 · IC025 +3.9 3/3 methods agree | Not in label — unassessed | serious n=19 | not reported in cached trials |
| Antidepressant discontinuation syndrome | 10 | 44.0 23.3–83.2ROR 44.0 · calibrated p 1e-4 ✓ | 38.8 EB05 22.5 · IC025 +2.7 3/3 methods agree | Labeled (related wording) related wording | – | not reported in cached trials |
| Feelings of worthlessness | 47 | 28.9 21.6–38.6ROR 28.9 · calibrated p 4e-4 ✓ | 27.6 EB05 21.6 · IC025 +4.0 3/3 methods agree | Not in label — unassessed | serious n=8 · 100% consumer | NCT00683800: 1/1,052 (0.1%) control |
| Serum serotonin increased | 12 | 27.2 15.3–48.3ROR 27.2 · calibrated p 0.001 ✓ | 25.3 EB05 15.2 · IC025 +2.7 3/3 methods agree | Likely indication confounding term in indications; also in warnings | – | NCT01432457: 1/300 (0.3%) on Desvenlafaxine (serious AE) |
| Hypoaesthesia eye | 19 | 26.2 16.6–41.3ROR 26.2 · calibrated p 1e-3 ✓ | 24.8 EB05 16.7 · IC025 +3.2 3/3 methods agree | Not in label — unassessed | serious n=17 | NCT00683800: 1/1,066 (0.1%) on Desvenlafaxine (serious AE) |
| Feeling guilty | 42 | 25.5 18.8–34.7ROR 25.5 · calibrated p 8e-4 ✓ | 24.5 EB05 18.9 · IC025 +3.8 3/3 methods agree | Not in label — unassessed | 100% consumer | not reported in cached trials |
| Drug screen false positive | 85 | 24.5 19.7–30.4ROR 24.5 · calibrated p 8e-4 ✓ | 23.6 EB05 19.7 · IC025 +4.0 3/3 methods agree | Lab value / disease marker | ♀ 53% (drug 77%) | not reported in cached trials |
| Electric shock sensation | 57 | 16.9 13.0–22.0ROR 16.9 · calibrated p 0.005 ✓ | 16.4 EB05 13.1 · IC025 +3.4 3/3 methods agree | Labeled adverse reaction exact term | serious n=27 · 75% consumer | not reported in cached trials |
| Negative thoughts | 62 | 16.8 13.1–21.6ROR 16.8 · calibrated p 0.005 ✓ | 16.4 EB05 13.2 · IC025 +3.5 3/3 methods agree | Not in label — unassessed | serious n=22 · 84% consumer | not reported in cached trials |
| Orgasm abnormal | 17 | 16.8 10.4–27.1ROR 16.8 · calibrated p 0.007 ✓ | 15.8 EB05 10.0 · IC025 +2.7 3/3 methods agree | Labeled adverse reaction exact term | – | NCT00683800: 3/1,066 (0.3%) on Desvenlafaxine |
| Tenosynovitis stenosans | 11 | 15.7 8.6–28.4ROR 15.7 · calibrated p 0.011 ✓ | 14.0 EB05 7.3 · IC025 +2.2 3/3 methods agree | Not in label — unassessed | serious n=11 | NCT00683800: 1/1,066 (0.1%) on Desvenlafaxine; 1/1,052 (0.1%) control |
| Hostility | 47 | 14.5 10.9–19.4ROR 14.6 · calibrated p 0.009 ✓ | 14.1 EB05 10.9 · IC025 +3.2 3/3 methods agree | Labeled adverse reaction exact term | serious n=30 | not reported in cached trials |
| Phobia | 21 | 14.5 9.4–22.3ROR 14.5 · calibrated p 0.011 ✓ | 13.6 EB05 9.0 · IC025 +2.7 3/3 methods agree | Not in label — unassessed | 100% consumer | not reported in cached trials |
| Bezoar | 25 | 14.4 9.7–21.4ROR 14.4 · calibrated p 0.011 ✓ | 13.7 EB05 9.4 · IC025 +2.8 3/3 methods agree | Not in label — unassessed | serious n=25 · ♀ 100% (drug 77%) | not reported in cached trials |
| Substance dependence | 12 | 14.2 8.0–25.2ROR 14.2 · calibrated p 0.015 ✓ | 12.6 EB05 6.8 · IC025 +2.2 3/3 methods agree | Not in label — unassessed | serious n=12 | not reported in cached trials |
| Withdrawal syndrome | 735 | 13.8 12.9–14.9ROR 14.2 · calibrated p 0.009 ✓ | 13.6 EB05 12.8 · IC025 +3.6 3/3 methods agree | Not in label — unassessed | serious PRR 11.3 · 75% consumer | NCT00683800: 1/1,052 (0.1%) control |
| Anorgasmia | 47 | 13.7 10.3–18.3ROR 13.7 · calibrated p 0.011 ✓ | 13.3 EB05 10.3 · IC025 +3.1 3/3 methods agree | Labeled adverse reaction exact term | – | NCT00683800: 10/1,066 (0.9%) on Desvenlafaxine |
| Crying | 619 | 13.5 12.5–14.6ROR 13.8 · calibrated p 0.010 ✓ | 13.2 EB05 12.4 · IC025 +3.6 3/3 methods agree | Not in label — unassessed | serious PRR 12.7 · 73% consumer | NCT00683800: 19/1,066 (1.8%) on Desvenlafaxine; 2/1,052 (0.2%) control |
| Iron overload | 18 | 13.2 8.3–21.1ROR 13.2 · calibrated p 0.016 ✓ | 12.1 EB05 7.6 · IC025 +2.5 3/3 methods agree | Not in label — unassessed | serious n=18 | not reported in cached trials |
| Blunted affect | 12 | 13.1 7.4–23.3ROR 13.1 · calibrated p 0.019 ✓ | 11.4 EB05 6.2 · IC025 +2.2 3/3 methods agree | Not in label — unassessed | serious n=11 | not reported in cached trials |
| Tachyphrenia | 56 | 12.8 9.8–16.7ROR 12.8 · calibrated p 0.014 ✓ | 12.4 EB05 9.8 · IC025 +3.1 3/3 methods agree | Not in label — unassessed | serious n=26 | not reported in cached trials |
| Dissociation | 120 | 12.6 10.5–15.1ROR 12.7 · calibrated p 0.014 ✓ | 12.3 EB05 10.6 · IC025 +3.3 3/3 methods agree | Not in label — unassessed | serious n=93 | NCT00683800: 2/1,066 (0.2%) on Desvenlafaxine |
| Yawning | 42 | 12.4 9.2–16.9ROR 12.5 · calibrated p 0.017 ✓ | 11.9 EB05 9.0 · IC025 +2.9 3/3 methods agree | Labeled adverse reaction exact term | serious n=15 | NCT00683800: 12/1,066 (1.1%) on Desvenlafaxine; 1/1,052 (0.1%) control |
| Product residue present | 81 | 12.1 9.7–15.1ROR 12.1 · calibrated p 0.017 ✓ | 11.8 EB05 9.7 · IC025 +3.1 3/3 methods agree | Reporting / coding artifact | serious n=19 · 72% consumer | not reported in cached trials |
| Pre-existing condition improved | 88 | 11.0 8.9–13.6ROR 11.1 · calibrated p 0.024 ✓ | 10.7 EB05 8.9 · IC025 +3.0 3/3 methods agree | Not in label — unassessed | serious n=48 | not reported in cached trials |
| Sleep-related eating disorder | 13 | 11.0 6.3–18.9ROR 11.0 · calibrated p 0.034 ✓ | 9.2 EB05 5.3 · IC025 +2.0 3/3 methods agree | Not in label — unassessed | – | not reported in cached trials |
| Coma scale abnormal | 39 | 10.8 7.9–14.8ROR 10.8 · calibrated p 0.028 ✓ | 10.2 EB05 7.6 · IC025 +2.7 3/3 methods agree | Not in label — unassessed | serious n=39 · ♀ 57% (drug 77%) · 100% clinician | not reported in cached trials |
| Bruxism | 70 | 10.3 8.1–13.0ROR 10.3 · calibrated p 0.032 ✓ | 9.9 EB05 8.0 · IC025 +2.9 3/3 methods agree | Labeled adverse reaction exact term | serious n=27 | NCT00683800: 3/1,066 (0.3%) on Desvenlafaxine |
| False positive investigation result | 13 | 10.2 5.9–17.6ROR 10.2 · calibrated p 0.043 ✓ | 8.4 EB05 4.9 · IC025 +2.0 3/3 methods agree | Lab value / disease marker | – | not reported in cached trials |
| Violence-related symptom | 20 | 10.1 6.5–15.8ROR 10.1 · calibrated p 0.039 ✓ | 9.0 EB05 5.9 · IC025 +2.3 3/3 methods agree | Not in label — unassessed | serious n=18 | not reported in cached trials |
| Medication residue present | 62 | 10.1 7.9–13.0ROR 10.1 · calibrated p 0.033 ✓ | 9.7 EB05 7.7 · IC025 +2.8 3/3 methods agree | Lab value / disease marker | serious n=12 · 73% consumer | not reported in cached trials |
| Serotonin syndrome | 244 | 10.1 8.9–11.4ROR 10.2 · calibrated p 0.031 ✓ | 9.9 EB05 8.9 · IC025 +3.1 3/3 methods agree | Labeled — boxed warning exact term | serious PRR 13.5 · ♀ 54% (drug 77%) | NCT01432457: 1/300 (0.3%) on Desvenlafaxine (serious AE) |
| Postural orthostatic tachycardia syndrome | 16 | 9.6 5.9–15.8ROR 9.6 · calibrated p 0.048 ✓ | 8.2 EB05 5.1 · IC025 +2.1 3/3 methods agree | Labeled (related wording) related wording | serious n=11 | not reported in cached trials |
| Decreased interest | 72 | 9.6 7.6–12.1ROR 9.7 · calibrated p 0.039 ✓ | 9.2 EB05 7.5 · IC025 +2.8 3/3 methods agree | Not in label — unassessed | serious n=16 · 83% consumer | NCT00683800: 1/1,066 (0.1%) on Desvenlafaxine |
| Post-traumatic stress disorder | 80 | 9.4 7.5–11.7ROR 9.4 · calibrated p 0.042 ✓ | 9.0 EB05 7.5 · IC025 +2.8 3/3 methods agree | Not in label — unassessed | serious n=74 | NCT00683800: 2/1,066 (0.2%) on Desvenlafaxine |
| Drug withdrawal syndrome | 1,052 | 9.4 8.8–9.9ROR 9.7 · calibrated p 0.036 ✓ | 9.2 EB05 8.8 · IC025 +3.1 3/3 methods agree | Not in label — unassessed | serious PRR 4.6 | NCT00683800: 1/1,052 (0.1%) control |
| Suicidal behaviour | 47 | 8.9 6.7–11.8ROR 8.9 · calibrated p 0.052 | 8.3 EB05 6.4 · IC025 +2.5 3/3 methods agree | Not in label — unassessed | serious n=46 | not reported in cached trials |
| Tension | 68 | 8.8 6.9–11.2ROR 8.8 · calibrated p 0.052 | 8.4 EB05 6.8 · IC025 +2.6 3/3 methods agree | Labeled — boxed warning exact term | serious n=14 · 89% consumer | NCT00683800: 1/1,066 (0.1%) on Desvenlafaxine (serious AE) |
Trial evidence (ClinicalTrials.gov)
✓ Trial adverse-event data found on ClinicalTrials.gov
Largest completed trials with posted results that list Desvenlafaxine as a study intervention. The right-hand column of the signal table shows whether each FAERS term was also recorded in these trials, with a real denominator (16 of 40 signal terms matched).
- NCT00683800 — Study Evaluating The Safety And Efficacy Of Desvenlafaxine Succinate For Vasomotor Symptoms In Menopausal Wome (N=2186, PHASE3; 1000 AE terms posted; arms: DVS SR 100 mg; Placebo)
- NCT01432457 — Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressiv (N=924, PHASE4; 22 AE terms posted; arms: Placebo; DVS SR 50 mg; DVS SR 100 mg)
Caveats: trial populations, doses and follow-up differ from the reporting population; AE terms are sponsor-coded and matched here by wording; absence from a trial list means the term was not reported above the sponsor's frequency threshold, not that it cannot occur.
Most frequently reported reactions
By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Drug ineffective (drug did not work) | 2,723 | 1.6 1.6–1.7ROR 1.7 · calibrated p 0.761 | 1.6 EB05 1.6 · IC025 +0.6 | Reporting / coding artifact | serious PRR 1.9 | not reported in cached trials |
| Nausea | 2,437 | 2.4 2.3–2.5ROR 2.6 · calibrated p 0.788 | 2.4 EB05 2.3 · IC025 +1.2 3/3 methods agree | Labeled adverse reaction exact term | serious PRR 2.4 | NCT00683800: 279/1,066 (26.2%) on Desvenlafaxine; 89/1,052 (8.5%) control |
| Headache | 1,943 | 2.4 2.3–2.5ROR 2.5 · calibrated p 0.796 | 2.4 EB05 2.3 · IC025 +1.2 3/3 methods agree | Labeled adverse reaction exact term | serious PRR 2.6 | NCT00683800: 1/1,066 (0.1%) on Desvenlafaxine |
| Dizziness | 1,895 | 3.0 2.9–3.1ROR 3.1 · calibrated p 0.585 | 3.0 EB05 2.9 · IC025 +1.5 3/3 methods agree | Labeled adverse reaction exact term | serious PRR 2.7 | NCT00683800: 1/1,052 (0.1%) control |
| Anxiety | 1,818 | 5.0 4.8–5.2ROR 5.3 · calibrated p 0.205 | 5.0 EB05 4.8 · IC025 +2.2 3/3 methods agree | Labeled adverse reaction exact term | serious PRR 4.8 | NCT00683800: 42/1,066 (3.9%) on Desvenlafaxine; 29/1,052 (2.8%) control |
| Fatigue (tiredness) | 1,677 | 1.7 1.6–1.8ROR 1.7 · calibrated p 0.790 | 1.7 EB05 1.6 · IC025 +0.7 | Labeled adverse reaction exact term | serious PRR 1.7 | NCT00683800: 1/1,066 (0.1%) on Desvenlafaxine (serious AE) |
| Insomnia (trouble sleeping) | 1,574 | 4.6 4.4–4.9ROR 4.9 · calibrated p 0.251 | 4.6 EB05 4.4 · IC025 +2.1 3/3 methods agree | Labeled adverse reaction exact term | serious PRR 4.2 | NCT00683800: 3/1,066 (0.3%) on Desvenlafaxine; 1/1,052 (0.1%) control |
| Feeling abnormal | 1,451 | 4.7 4.5–5.0ROR 4.9 · calibrated p 0.240 | 4.7 EB05 4.5 · IC025 +2.1 3/3 methods agree | Labeled (related wording) related wording | serious PRR 5.2 · 72% consumer | NCT00683800: 6/1,066 (0.6%) on Desvenlafaxine; 3/1,052 (0.3%) control |
| Depression | 1,388 | 4.8 4.5–5.0ROR 5.0 · calibrated p 0.237 | 4.7 EB05 4.5 · IC025 +2.2 3/3 methods agree | Labeled — boxed warning exact term | serious PRR 5.7 | NCT00683800: 1/1,066 (0.1%) on Desvenlafaxine (serious AE) |
| Off label use (used outside approved label) | 1,054 | 0.9 0.9–1.0ROR 0.9 · calibrated p 0.273 | 0.9 EB05 0.9 · IC025 -0.2 PRR-only: not supported by EBGM or IC | Reporting / coding artifact | serious PRR 1.4 | not reported in cached trials |
| Drug withdrawal syndrome | 1,052 | 9.4 8.8–9.9ROR 9.7 · calibrated p 0.036 ✓ | 9.2 EB05 8.8 · IC025 +3.1 3/3 methods agree | Not in label — unassessed | serious PRR 4.6 | NCT00683800: 1/1,052 (0.1%) control |
| Malaise (feeling unwell) | 1,041 | 1.9 1.7–2.0ROR 1.9 · calibrated p 0.881 | 1.8 EB05 1.8 · IC025 +0.8 | Not in label — unassessed | serious PRR 2.0 · 73% consumer | NCT00683800: 8/1,066 (0.8%) on Desvenlafaxine; 4/1,052 (0.4%) control |
| Diarrhoea (diarrhea) | 960 | 1.2 1.1–1.2ROR 1.2 · calibrated p 0.422 | 1.2 EB05 1.1 · IC025 +0.1 | Labeled adverse reaction exact term | serious PRR 1.2 | NCT00683800: 79/1,066 (7.4%) on Desvenlafaxine; 56/1,052 (5.3%) control |
| Condition aggravated | 941 | 2.4 2.3–2.6ROR 2.5 · calibrated p 0.817 | 2.4 EB05 2.3 · IC025 +1.2 3/3 methods agree | Reporting / coding artifact | serious PRR 2.3 | not reported in cached trials |
| Pain | 915 | 1.2 1.1–1.2ROR 1.2 · calibrated p 0.419 | 1.2 EB05 1.1 · IC025 +0.1 | Not in label — unassessed | serious PRR 1.5 | NCT00683800: 1/1,052 (0.1%) control (serious AE) |
Unlabeled candidate signals
These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.
- Medication residue — n=533, PRR 200.3
- Persistent genital arousal disorder — n=20, PRR 73.3
- Feelings of worthlessness — n=47, PRR 28.9 (also seen in trial arm)
- Feeling guilty — n=42, PRR 25.5
- Negative thoughts — n=62, PRR 16.8
- Phobia — n=21, PRR 14.5
- Bezoar — n=25, PRR 14.4
- Withdrawal syndrome — n=735, PRR 13.8 (also seen in trial arm)
- Crying — n=619, PRR 13.5 (also seen in trial arm)
- Tachyphrenia — n=56, PRR 12.8
Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.
Common questions
What are the most reported side effects of Desvenlafaxine?
In FDA FAERS, the most frequently co-reported reaction terms for Desvenlafaxine are nausea, headache, dizziness, anxiety, fatigue, insomnia. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.
Does Desvenlafaxine have an FDA boxed warning?
Yes. The current FDA label carries a boxed warning: SUICIDAL THOUGHTS AND BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies. These studies did not show an increase in the ris.
Do FAERS signals prove that Desvenlafaxine causes these side effects?
No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.
Sources & methods
- FDA label via openFDA (set ID 2dce1542-ead5-1b24-e063-6294a90a6df0, effective 20250217; matched on
openfda.generic_name.exact:"DESVENLAFAXINE") - Bayesian shrinkage measures computed offline over all 1,317,300 cached pairs: BCPNN information component (IC, with Norén closed-form IC025) and MGPS empirical-Bayes geometric mean (EBGM, EB05) with a two-component gamma prior fitted by maximum marginal likelihood (α₁=0.57, β₁=0.02, α₂=1.42, β₂=0.70, w=0.17); unstratified
- FAERS pair statistics from the OpenPV build of 2026-09-14 (openFDA
count=aggregation, fieldpatient.drug.openfda.generic_name.exact, 1,150 reaction terms, min 3 co-reports); PRR/ROR with 95% CI, chi-square with Yates correction - Serious-only and stratified counts (serious:1, patient.patientsex, primarysource.qualification) from openFDA count queries; serious-only PRR uses the drug serious report total and the term global serious total (N_serious=11,882,979); strata shown only when n ≥ 20
- Seriousness and sex counts from openFDA
count=serious,patient.patientsex,seriousnessdeath - ClinicalTrials.gov API v2 (query
DESVENLAFAXINE, results-bearing studies sorted by enrollment)
Page generated 2026-10-14. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.